Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan 75 mg outcomes study in pulmonary arterial hypertension
MOH_2020-06-21_009039Phase 3Active, not recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of macitentan in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Primary endpoint not reported in registry entry. Started Apr 2020; status: active, not recruiting.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2020-06-21_009039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-21_009039.